SCHEMBL3057079

SCHEMBL3057079

CCOC(=O)C(C)=Cc1c(Cl)cc(C(=O)O)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
POLB P06746 2/20 0.40
ALOX15 P16050 1/20 0.40
HTT P42858 1/20 0.40
TTR P02766 1/20 0.40
ALDH1A1 P00352 3/20 0.39
TPMT P51580 1/20 0.39
GPR35 Q9HC97 1/20 0.38
LMNA P02545 3/20 0.38
KDM4E B2RXH2 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
PLAU P00749 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
GAA P10253 1/20 0.38
MCL1 Q07820 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
S1PR4 O95977 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3057078 1.00 MEN1 (0.41) MEN1KMT2APOLBALOX15HTT
SCHEMBL13101067 0.93 MEN1 (0.39) MEN1KMT2APOLBALOX15HTT
SCHEMBL3064697 0.85 GPR35 (0.50) MEN1KMT2AALDH1A1GPR35LMNA
SCHEMBL3064694 0.85 GPR35 (0.50) MEN1KMT2AALDH1A1GPR35LMNA
SCHEMBL16224162 0.79 TTR (0.48) TTRTPMTGPR35PLAU
SCHEMBL15199397 0.79 TTR (0.48) TTRTPMTGPR35PLAU
SCHEMBL13101313 0.78 GPR35 (0.47) MEN1KMT2APOLBALDH1A1GPR35
SCHEMBL5694701 0.74 MEN1 (0.54) MEN1KMT2APOLBALDH1A1LMNA
SCHEMBL5694705 0.74 MEN1 (0.54) MEN1KMT2APOLBALDH1A1LMNA
SCHEMBL14062035 0.71 CYP2C9 (0.51) MEN1KMT2APOLBALOX15HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184279-B1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF SHIONOGI & CO (JP) 2014-11-12 EP claimed
US-20100267783-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) 2010-10-21 US claimed
EP-2184279-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF Shionogi&Co., Ltd. (JP) 2010-05-12 EP claimed
CN-122010730-A Preparation method of key intermediate of Lutrepah 重庆常捷医药有限公司 2026-05-12 CN disclosed
CN-109415371-B 2-amido thiazole derivative and preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2021-07-09 CN disclosed
CN-108495852-B 2-amido thiazole derivatives, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2021-06-15 CN disclosed
US-20190315771-A1 NOVEL 2-ACYLAMINOTHIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2019-10-17 US disclosed
EP-3511332-A1 NOVEL 2-ACYLAMINOTHIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2019-07-17 EP disclosed
US-8889722-B2 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor SHIONOGI & CO., LTD. (JP) 2014-11-18 US disclosed
EP-2184279-B1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF SHIONOGI & CO (JP) 2014-11-12 EP disclosed
US-8530668-B2 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor SHIONOGI & CO., LTD. (JP) 2013-09-10 US disclosed
US-20130217885-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR SHIONOGI & CO., LTD. (JP) 2013-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267783-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR MPL, TEK, THPO MEN1 1357/4885KMT2A 3667/4885POLB 3827/4885
US-20190315771-A1 NOVEL 2-ACYLAMINOTHIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF TEK, MPL, THPO MEN1 1224/4885KMT2A 2561/4885POLB 4591/4885
US-20130217885-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR MPL, TEK, THPO MEN1 1400/4885KMT2A 3659/4885POLB 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.